GHRH: A Literature Course in Six Modules

This course organises the published literature on growth hormone-releasing hormone (GHRH) into six modules. It describes what researchers studied, in which models, and what they reported — not what anyone should do. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about health, medication or research participation.

MODULE 1 — What GHRH Is, and How It Has Been Studied

Definition and class

GHRH is a hypothalamic releasing hormone: a small peptide hormone produced by neurons in the hypothalamus and delivered through the hypophyseal portal circulation to the anterior pituitary, where it binds the GHRH receptor (GHRH-R), a class B G-protein-coupled receptor. Its best-known physiological role is the stimulation of growth hormone (GH) synthesis and secretion from pituitary somatotrophs. In the literature the native human peptide is usually written as GHRH(1-44); a shorter N-terminal fragment, GHRH(1-29), retains receptor binding and is the backbone of several synthetic analogues.

Where GHRH comes from

The developmental origin of the GHRH-producing neuron population has been mapped in mice: a 2018 Nature Communications study reported that the transcription factors Dlx1/2 and Otp coordinate the production of hypothalamic GHRH- and AgRP-neurons (PMID 29795232). That work established GHRH neurons as a genetically specified population rather than a diffuse hypothalamic function.

Forms studied in the literature

Published work on GHRH falls into four broad categories of molecule:

• Native GHRH peptides — used in physiological and diagnostic stimulation studies, including a study of GH responses to GHRH testing in normal aging and GH-deficient adults (PMID 20843274).
• GHRH agonists (synthetic analogues) — studied for receptor-mediated effects in tissue and tumour models, including the reported effect of GHRH and its agonists on hepatic and tumoral IGF-1 secretion (PMID 29983893).
• GHRH antagonists — peptide analogues that block GHRH-R, examined in mouse behaviour models (PMID 37998350) and in lung endothelial barrier models (PMID 31578921).
• Endogenous GHRH excess — studied as a disease state, for example the analysis of GHRH excess and blockade in X-linked acrogigantism (X-LAG) syndrome (PMID 26671997).

GHRH biology has also been described outside the hypothalamic-pituitary axis. A comparative endocrinology study reported co-localization and action of GH and GHRH in the chicken testis (PMID 24508498), and a 2025 review examined GHRH in the context of the prostate (PMID 39505776).

Limits of the evidence in Module 1

Definitions and origins are well established in animal and cell systems, but the verified literature reviewed here does not provide a single unified human mapping of GHRH expression across all tissues. Statements about extrapituitary GHRH mostly derive from individual tissues or species (chicken testis, prostate tissue) and were not designed to describe whole-body physiology.

MODULE 2 — Mechanism as Described in the Literature

The classical pituitary route

In the canonical description, GHRH binds GHRH-R on somatotrophs, raises intracellular cAMP, activates protein kinase A, and increases both GH gene transcription and secretion of stored GH. Circulating GH then acts on the liver and other tissues, where insulin-like growth factor 1 (IGF-1) is produced. Because of that architecture, many GHRH papers use GH output or IGF-1 as the measured endpoint rather than GHRH itself.

A vesicle-mediated pathway to the liver

The pituitary-to-liver link is not purely hormonal in every model. A 2024 Journal of Nanobiotechnology study reported that GHRH-stimulated pituitary small extracellular vesicles inhibited hepatocyte proliferation and IGF-1 expression through their cargo microRNA miR-375-3p (PMID 39438882). The researchers therefore described a second, vesicle-borne channel of communication that operates alongside GH.

Direct effects on IGF-1 secretion

A 2018 Oncotarget study reported that GHRH and its agonists inhibited hepatic and tumoral secretion of IGF-1 (PMID 29983893). That finding is a reminder that GHRH-R signalling in peripheral tissue does not simply mirror what the pituitary axis does; direction of effect depended on the tissue and the endpoint the study measured.

Extrapituitary receptor signalling

Several papers characterised GHRH-R signalling in cancer cells. Researchers reported that GHRH promoted metastatic phenotypes in prostate cancer cells through transactivation of EGFR/HER2 (PMID 28193499), and a separate immunohistochemistry study reported GHRH-R expression in triple-negative breast cancer as a potentially targetable biomarker (PMID 29206714). On the barrier side, a 2019 Tissue Barriers paper reported that GHRH antagonists supported lung endothelial barrier function (PMID 31578921), implying tonic GHRH-R signalling in endothelium.

Limits of the evidence in Module 2

Mechanistic work in this set is dominated by cell lines, isolated tissue and rodent models. The vesicle and IGF-1 findings were reported in experimental systems and were not tested as mechanisms in healthy humans. No paper in this set measured whether the same signalling steps occur at physiological GHRH concentrations in intact human tissue.

MODULE 3 — Reported Outcomes, Study by Study

The table below lists what each verified paper studied and what it reported. No benefit for any person is implied; these are experimental endpoints.

How to read this table

Two features stand out. First, the direction of a GHRH effect depended on the system: GHRH stimulated the pituitary axis in classical physiology, yet researchers reported inhibition of hepatic and tumoral IGF-1 secretion by GHRH and its agonists in one experimental setting (PMID 29983893). Second, a substantial share of GHRH literature is oncology-facing: the receptor was studied as a target, and blockade — not stimulation — was the intervention being tested in the antagonist papers (PMID 31578921, PMID 37998350).

Limits of the evidence in Module 3

Most of these reports are single studies in single models. Cell-line and rodent endpoints do not establish outcomes in people. Behavioural, barrier, wound-repair and tumour endpoints were measured in separate experiments that cannot be combined into a general claim, and the human work in this set is small, physiological or observational rather than outcome-driven.

MODULE 4 — GHRH Side Effects: What Studies Report

The verified literature reviewed here does not contain a systematic adverse-event table for GHRH administration in healthy people. What it does contain are biological risk signals and phenotypes associated with too much GHRH signalling, too little, or with receptor blockade.

Signals associated with GHRH excess

Endogenous GHRH excess has been described as a pathological state: researchers analysed GHRH excess and blockade in X-LAG syndrome, a disorder of early-onset growth hormone hypersecretion (PMID 26671997). In the tumour-biology literature, GHRH signalling was reported to promote metastatic phenotypes in prostate cancer cells via EGFR/HER2 transactivation (PMID 28193499), and GHRH-R was reported to be expressed in triple-negative breast cancer tissue (PMID 29206714). A 2025 review discussed GHRH in relation to the prostate (PMID 39505776). Together these papers describe why receptor-bearing tumour tissue is treated in the literature as a theoretical concern rather than a settled clinical risk estimate.

Signals associated with GHRH deficiency or blockade

A 2023 Cells study reported effects of both GHRH deficiency and GHRH antagonism on emotional disorders in mice (PMID 37998350), indicating that loss of GHRH signalling in that model was not behaviourally neutral. On the other side, GHRH antagonists were reported to support lung endothelial barrier function (PMID 31578921), a reminder that blockade produced tissue-dependent consequences.

Downstream metabolic signals

A 2024 study reported that GHRH-stimulated pituitary small extracellular vesicles inhibited hepatocyte proliferation and IGF-1 expression through miR-375-3p (PMID 39438882), showing that stimulation of the axis can produce inhibitory effects in the liver in that experimental system.

Limits of the evidence in Module 4

None of the papers above is a safety trial. There are no incidence rates, no dose-response toxicity curves and no human tolerability data in this verified set. Mouse behavioural phenotypes and cell-line signalling do not translate directly into clinical adverse events, and the absence of reported harm in a mechanistic paper is not evidence of safety.

MODULE 5 — Pharmacokinetics, Where Data Exist

Pharmacokinetics is the weakest area of the verified literature gathered here. None of the papers reported absorption, half-life, clearance, volume of distribution or bioavailability values for GHRH or its analogues, so no such numbers are stated on this page.

What exists instead is pharmacodynamic testing. A study in normal aging and GH-deficient adults reported a difference in GH response to GHRH stimulation testing following subacute GHRH treatment, and the authors discussed what that difference might mean for possible therapeutic use of GHRH or its analogues in elderly subjects (PMID 20843274). That design measures how responsive the pituitary is, not how long the peptide persists in plasma.

Two mechanistic observations are relevant to how GHRH's effects are distributed in time and space rather than to classical PK. First, researchers reported a vesicle-mediated route from the stimulated pituitary to hepatocytes (PMID 39438882), meaning some downstream effects may not track plasma peptide concentration at all. Second, the reported inhibition of hepatic and tumoral IGF-1 secretion by GHRH and its agonists (PMID 29983893) indicates local receptor exposure matters, not only systemic levels.

Limits of the evidence in Module 5

Because no verified paper here provides PK parameters, any statement about onset, duration or dosing interval for GHRH would be unsupported. Peptide PK also differs by analogue, formulation, route and species, so figures from one molecule would not describe another.

MODULE 6 — Regulatory Status, Stated Factually

Approved products

GHRH-related medicines have existed as approved products. Sermorelin, a synthetic GHRH(1-29) analogue, was previously marketed in the United States as a prescription product and was later discontinued as a commercial branded product. Tesamorelin, a stabilised GHRH analogue, holds US Food and Drug Administration approval as a prescription injectable with a specific labelled indication in HIV-associated lipodystrophy. GHRH peptides have also been used historically as diagnostic agents in pituitary stimulation testing, the general study design used in the human work cited above (PMID 20843274).

Research-use-only material

Many GHRH agonists and antagonists appearing in the literature — including the antagonist compounds used in mouse behaviour and endothelial barrier studies (PMID 37998350, PMID 31578921) — are investigational molecules. Material labelled "research use only" is not approved for human administration, is not manufactured to drug-product standards, and is restricted to laboratory research by that labelling.

Compounding

In the United States, compounded preparations are governed by sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act. A bulk drug substance generally must appear on an applicable FDA list, be a component of an approved drug, or have a USP monograph to be eligible for compounding, and FDA has publicly categorised a number of peptide bulk substances by the level of concern identified during its review. Eligibility status changes over time and differs by substance and by facility type.

This section describes regulatory categories for educational purposes and is not legal advice.

Limits of the evidence in Module 6

Regulatory status is jurisdiction-specific and dated; approval of one GHRH analogue for one labelled indication says nothing about the evidence base, legality or safety of other analogues or of unapproved uses. None of the cited papers addressed regulatory questions.

What the Studies Did Not Test

Reading the twelve verified papers together, the gaps are as informative as the findings:

1. No healthy-population outcome trials. The human material in this set involved GH-deficient adults, aging adults undergoing stimulation testing (PMID 20843274) and a disease cohort with GHRH excess (PMID 26671997) — not healthy volunteers taking GHRH for performance, body composition or aging endpoints.
2. No dose-ranging or long-term safety data. No paper here reported tolerability over months or years, and none quantified adverse-event frequency.
3. No pharmacokinetic characterisation. Half-life, exposure and route comparisons are absent from this set.
4. No cross-species confirmation for several key findings. The vesicle/miR-375-3p mechanism (PMID 39438882), the behavioural phenotypes (PMID 37998350), the testicular co-localization (PMID 24508498) and the developmental transcription-factor work (PMID 29795232) were reported in animal or cell systems.
5. No clinical endpoint for wound repair. The 2011 article addressed GHRH and wound healing conceptually (PMID 21509187) rather than as a controlled clinical outcome.
6. No resolution of the oncology question. Receptor expression in tumour tissue (PMID 29206714) and pro-metastatic signalling in cell lines (PMID 28193499) describe biology, not risk in individuals.

Anyone comparing these reports to a personal situation should do so with a licensed physician; this course summarises literature and does not recommend, endorse or describe use of any compound.

References

• GHRH-stimulated pituitary small extracellular vesicles inhibit hepatocyte proliferation and IGF-1 expression by its cargo miR-375-3p (Journal of Nanobiotechnology, 2024)
• GHRH and the prostate (Reviews in Endocrine & Metabolic Disorders, 2025)
• GHRH and wound healing (Communicative & Integrative Biology, 2011)
• Effects of GHRH Deficiency and GHRH Antagonism on Emotional Disorders in Mice (Cells, 2023)
• GHRH antagonists support lung endothelial barrier function (Tissue Barriers, 2019)
• Dlx1/2 and Otp coordinate the production of hypothalamic GHRH- and AgRP-neurons (Nature Communications, 2018)
• Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1 (Oncotarget, 2018)
• Expression of GHRH-R, a Potentially Targetable Biomarker, in Triple-negative Breast Cancer (Applied Immunohistochemistry & Molecular Morphology, 2018)
• Growth hormone (GH) and GH-releasing hormone (GHRH): Co-localization and action in the chicken testis (General and Comparative Endocrinology, 2014)
• Difference in growth hormone response to growth hormone-releasing hormone (GHRH) testing following GHRH subacute treatment in normal aging and growth hormone-deficient adults (Immunopharmacology and Immunotoxicology, 2011)
• Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells (Molecular and Cellular Endocrinology, 2017)
• GHRH excess and blockade in X-LAG syndrome (Endocrine-Related Cancer, 2016)